{"product_id":"animalcaregroup-five-forces-analysis","title":"Animalcare Group Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Strategic Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eAnimalcare Group faces moderate buyer power and supplier influence, with regulatory barriers and niche product differentiation tempering new entrants and substitutes; competitive rivalry is steady but innovation-linked. This snapshot highlights key tensions shaping margins and growth potential. Unlock the full Porter's Five Forces Analysis to explore Animalcare Group’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized API Manufacturers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAnimalcare depends on a small global set of API makers that meet strict veterinary standards, giving suppliers pricing and timing leverage; switching triggers costly quality audits and regulatory re-filings that can take 6–12 months. By late 2025, management cites supply-chain stability as a priority after specialized chemical costs rose ~8% YoY amid trade policy shifts. Suppliers’ concentration means a single-source disruption could hit gross margins by an estimated 150–250 basis points.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAnimalcare relies on contract manufacturing organizations (CMOs) for about 60% of its pharma output to stay capital-light; that reliance gives CMOs leverage via specialized tech and the ~£5–15m cost to transfer a production line, raising switching barriers. European CMO capacity tightened after 2020, with average lead times of 20–30 weeks in 2024, allowing providers to push pricing increases of 3–7% annually and tighten delivery terms.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property Licensors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpa portion of animalcare group late-2025 pipeline relies on licensing deals with biotech and academic licensors who control patents that drive therapeutic differentiation giving them high leverage.\u003e\n\u003cproyalty negotiations and territorial rights skew toward ip holders industry benchmarks show median biotech royalty rates of upfronts averaging per asset in\u003e\n\u003cpthis supplier power raises animalcare cogs risk and margin pressure if key licensors demand higher royalties or narrower commercialization zones.\u003e\n\u003c\/pthis\u003e\u003c\/proyalty\u003e\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance Service Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSuppliers of clinical-trial data and regulatory-submission services are critical for Animalcare Group to maintain product registrations across the UK and EU; in 2024 around 60–70% of veterinary MA submissions relied on external consultants per industry surveys.\u003c\/p\u003e\n\u003cp\u003eDeep knowledge of the Veterinary Medicines Directorate and European Medicines Agency narrows the supplier pool—estimated under 30 specialist firms—letting them sustain firm pricing for essential dossiers and updates.\u003c\/p\u003e\n\u003cp\u003eHigh switching costs and regulatory risk mean Animalcare faces limited negotiation power; typical service contracts rose 5–8% year-on-year in 2023–24, raising OPEX for regulatory maintenance.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEssential for MA retention across jurisdictions\u003c\/li\u003e\n\u003cli\u003eFewer than ~30 qualified providers (2024 est.)\u003c\/li\u003e\n\u003cli\u003e60–70% of submissions outsourced (2024)\u003c\/li\u003e\n\u003cli\u003eContract prices up 5–8% YoY in 2023–24\u003c\/li\u003e\n\u003cli\u003eHigh switching costs, low bargaining power\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLogistics and Cold Chain Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLogistics and cold-chain providers hold meaningful supplier power for Animalcare Group because maintaining 2–8°C and frozen supply chains is critical for sensitive veterinary medicines; global cold-chain market hit USD 219.6bn in 2024, rising ~8% YoY.\u003c\/p\u003e\n\u003cp\u003eFuel cost volatility (diesel up ~12% in 2023–24) and shortages of trained cold-chain staff raised transport premiums, concentrating power among certified providers.\u003c\/p\u003e\n\u003cp\u003eAnimalcare must secure multi-year contracts, KPIs for temperature excursions, and local redundancy to protect product integrity and on-time delivery to clinics.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCold-chain market: USD 219.6bn (2024)\u003c\/li\u003e\n\u003cli\u003eDiesel +12% impact on transport costs (2023–24)\u003c\/li\u003e\n\u003cli\u003eUse multi-year contracts, SLA temperature KPIs\u003c\/li\u003e\n\u003cli\u003eBuild local redundancy and certified partners\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier concentration risks threaten Animalcare margins — single-source shock could cost 150–250bps\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers (APIs, CMOs, IP licensors, regulatory consultants, cold-chain) hold high bargaining power versus Animalcare—concentrated pools, high switching costs (line transfer £5–15m; audits 6–12 months), and rising prices (specialty chemicals +8% YoY; CMO +3–7%; service +5–8%) risk 150–250bps gross margin hit from single-source disruption.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSupplier\u003c\/th\u003e\n\u003cth\u003eKey stat\u003c\/th\u003e\n\u003cth\u003e2024–25 impact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPIs\u003c\/td\u003e\n\u003ctd\u003e6–12m switch time\u003c\/td\u003e\n\u003ctd\u003eSpecialty chemical +8% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMOs\u003c\/td\u003e\n\u003ctd\u003e60% output; 20–30wk lead\u003c\/td\u003e\n\u003ctd\u003ePrice +3–7%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensors\u003c\/td\u003e\n\u003ctd\u003eRoyalty 5–10%\u003c\/td\u003e\n\u003ctd\u003eUpfronts £1–3m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory firms\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;30 firms; 60–70% outsourced\u003c\/td\u003e\n\u003ctd\u003eFees +5–8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold-chain\u003c\/td\u003e\n\u003ctd\u003eMarket USD219.6bn\u003c\/td\u003e\n\u003ctd\u003eFuel +12% transport cost\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored exclusively for Animalcare Group, this Porter's Five Forces overview uncovers competitive drivers, supplier and buyer power, substitute threats, and entry barriers to assess pricing pressure, profitability, and strategic vulnerabilities in the veterinary pharmaceuticals and animal health market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Porter's Five Forces snapshot for Animalcare Group—pinpoint supplier, buyer, and competitive pressures to fast-track strategic decisions and presentation-ready summaries.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVeterinary Corporate Consolidation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe rise of UK and EU corporate vet groups has concentrated buying power: by end-2025 the top 10 groups account for ~45% of clinic revenue and negotiate 10–18% average volume discounts, forcing Animalcare to accept tighter margins or secure preferred-supplier contracts; losing those contracts risks cutting \u0026gt;30% of sales in some product lines, so these groups are effectively indispensable partners for market access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOnline Pharmacy Transparency\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePet owners compare chronic medication prices online—searches for pet meds rose 42% in 2024—forcing clinics to match retail prices and pressuring Animalcare to keep wholesale prices low to protect clinic margins.\u003c\/p\u003e\n\u003cp\u003eIn 2025 digital price transparency means brands need clinical differentiation to keep premiums; without it, margins compress—veterinary channels report average retail discounting of 8–12% vs list in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLivestock Producer Cooperatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLivestock producer cooperatives aggregate purchases—US farm co-ops bought about $110bn in inputs in 2023—so they drive price-focused procurement for anti-infectives and ID products, cutting manufacturers’ margin power.\u003c\/p\u003e\n\u003cp\u003eCollective bargaining is strongest in livestock ID where tags and readers are commoditized; bulk tenders often force single-digit price concessions and favor scale players.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow Switching Costs for Generics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLow switching costs for generic pain management and basic anti-infectives mean vets can swap suppliers with little friction, which is significant because Animalcare faces generic competition on roughly 40–60% of its SKU portfolio as of 2024.\u003c\/p\u003e\n\u003cp\u003eThis buyer flexibility lets clinics push for discounts, bundled promos, or faster credit terms, keeping margins under pressure and capping Animalcare’s ability to raise prices beyond inflation (UK CPI 2024: 3.9%).\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~40–60% SKUs face generics\u003c\/li\u003e\n\u003cli\u003eClinics negotiate price\/promos\u003c\/li\u003e\n\u003cli\u003eLimits price hikes above ~3–4%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Efficacy and Brand Trust\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eVeterinary professionals put clinical outcomes first, so Animalcare’s proven safety and efficacy record reduces pure price-based bargaining despite 2025 procurement pressures.\u003c\/p\u003e\n\u003cp\u003eTrusted brands keep practitioners from switching: Animalcare’s repeat-prescription rate (estimated 68% in 2024) and post-market safety reports lower buyer leverage.\u003c\/p\u003e\n\u003cp\u003eClinical loyalty offsets procurement cost-cutting, letting Animalcare retain pricing power in tender negotiations.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePractitioner-focused demand\u003c\/li\u003e\n\u003cli\u003e68% repeat-prescription rate (2024 est.)\u003c\/li\u003e\n\u003cli\u003eBrand reduces switching\u003c\/li\u003e\n\u003cli\u003eLimits procurement bargaining\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVet consolidation, savvy owners cap pricing: discounts 10–18%, hikes limited to 3–4%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eConcentrated vet groups (top 10 ≈45% revenue by end-2025) and price-savvy pet owners push 8–18% discounts; 40–60% SKUs face generics, capping price hikes near 3–4%, while 68% repeat prescriptions (2024 est.) and clinical trust preserve some pricing power.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop-10 clinic share (2025)\u003c\/td\u003e\n\u003ctd\u003e≈45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinic discounts\u003c\/td\u003e\n\u003ctd\u003e10–18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeneric-exposed SKUs (2024)\u003c\/td\u003e\n\u003ctd\u003e40–60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRepeat Rx rate (2024 est.)\u003c\/td\u003e\n\u003ctd\u003e68%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eAnimalcare Group Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Animalcare Group Porter’s Five Forces analysis you’ll receive immediately after purchase—no placeholders, no mockups, fully formatted and ready for download.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747415896441,"sku":"animalcaregroup-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/animalcaregroup-five-forces-analysis.png?v=1772198293","url":"https:\/\/matrixbcg.com\/products\/animalcaregroup-five-forces-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}